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Abstract
Little is known about temporal changes in the epidemiology of Staphylococcus aureus bacteraemia. The objective of the present study
was to analyse changes in the incidence and mortality of adult S. aureus bacteraemia in Iceland. Individuals 18 years or older with a
positive blood culture for S. aureus between 1 January 1995 and 31 December 2008 were identiﬁed, with the participation of all clinical
microbiological laboratories performing blood cultures in Iceland. Infections were categorized as nosocomial, healthcare-associated or
community-acquired. National population statistics and dates of death were retrieved from the National Registry. During the study
period, 692 individuals from 19 institutions had 721 distinct episodes of S. aureus bacteraemia. The incidence rose from 22.7 to 28.9
per 100 000 per year during the period (p 0.012). Nosocomial infections comprised 46.3% of cases, 14.6% were healthcare-associated,
and 39.1% were community-acquired. The proportion of nosocomial infections decreased during the period (p <0.001), whereas an
increase was seen in the proportion of community-acquired infections (p <0.001). All-cause 30-day mortality decreased from 25.0% to
8.1% (p 0.001) and 1-year mortality decreased from 37.0% to 27.9% (p 0.061) between the periods 1995–1996 and 2007–2008. Four
cases of bacteraemia caused by methicillin-resistant S. aureus were seen (0.6%), none of which was fatal. In conclusion, there was a
signiﬁcant increase in the incidence of S. aureus bacteraemia in Iceland between 1995 and 2008. Concomitantly, there was a signiﬁcant
reduction in mortality, towards one of the lowest reported. Further studies are needed to understand the basis for these changes.
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Introduction
Staphylococcus aureus is a major cause of both nosocomial
and community-acquired bloodstream infections [1]. How-
ever, studies on the incidence of S. aureus bacteraemia (SAB)
are sparse [1–12]. SAB-associated mortality was over 80% in
the pre-antibiotic era, and today the infection still carries a
signiﬁcant risk of morbidity and mortality [13]. Reported
mortalities generally range from 11% to 40% in developed
countries [2–4,12,14–18]. However, most studies have been
institution-based rather than population-based, and have
rarely assessed long-term outcome [16,19,20]. Despite the
importance of the infection, few data have been published
regarding temporal changes in the incidence and mortality of
SAB [2–4,9,11,14,17].
The objective of the present study was to evaluate trends in
the incidence, short-term mortality and long-term mortality of
SAB in Iceland during 1995–2008. A second objective was to
assess the proportions of nosocomial and healthcare-associ-
ated infections and trends in antimicrobial susceptibility.
Materials and Methods
Study population and protocol
Iceland is an island in the North Atlantic Ocean with an area of
103 000 km2 and a population of just over 300 000. The
majority of inhabitants live in the south-west, around the capi-
tal. The healthcare system is run by the government, with a uni-
versity hospital in Reykjavik and a teaching hospital in Akureyri.
Smaller regional hospitals are spread around the country.
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Cases of SAB occurring between 1 January 1995 and 31
December 2008 were identiﬁed retrospectively by clinical
microbiological laboratories that perform blood cultures in
Iceland. All collected blood cultures in the country are sent
to one of two laboratories. Individuals 18 years or older
with a positive blood culture for S. aureus were included.
Cases were identiﬁed from 19 institutions, with the majority
of cases being from the hospitals in Reykjavik. Information
on admission and discharge dates was obtained from medical
records. Information on hospitalizations 3 months prior to
the bacteraemia was obtained for those who were diagnosed
within 2 days from admission.
Information on the national population and dates of death
was available from the Icelandic National Registry. During
the study period, the number of people aged ‡18 years
increased from 188 888 to 238 587 (26.3%), with their mean
age increasing from 30.9 to 33.5 years. The number of peo-
ple aged ‡50 years rose from 62 360 to 90 459 (45.1%), i.e.
from 33.0% to 37.9% of the adult population.
The study was approved by the National Bioethics Com-
mittee and Data Protection Authority.
Deﬁnitions
An episode of SAB was deﬁned by the isolation of S. aureus
from at least one blood culture bottle. The blood culture
systems used at the university hospital were Bactec in 1995,
Difco ESP in 1996–2002 and BacT/Alert from 2002, and at
the teaching hospital they were Septi-Chek in 1995–1999,
Difco ESP in 1999–2008 and BacT/Alert from 2008. All posi-
tive blood cultures were considered to represent clinically
signiﬁcant SABs. Repeated isolation of S. aureus within
90 days after the ﬁrst isolation was thought to represent the
same episode unless the isolate was found to have a different
antimicrobial susceptibility proﬁle. For those diagnosed in the
ﬁrst 3 months of 1995, it was veriﬁed that the SAB was not
a relapse of an infection just prior to 1995.
Nosocomial bacteraemia was deﬁned as one for which the
sample for the ﬁrst positive blood culture was drawn more
than 2 days after hospital admission. Positive cultures from
samples drawn 2 days or less after hospital discharge following
a minimum of a 2-day stay were also deﬁned as nosocomial.
Healthcare-associated bacteraemia was deﬁned as one that
was not nosocomial but that occurred in individuals who had
been admitted to hospital for more than 2 days in the 90 days
prior to bacteraemia. Community-acquired bacteraemia was
deﬁned as neither nosocomial nor healthcare-associated.
Statistical analysis
The data are given in terms of number of observations,
medians, quartiles, and range and means. Linear time trends
in incidence and mortality rates were estimated using the
chi-squared trend test. Time trends in other data and associ-
ations between variables were evaluated by Kendall’s corre-
lation. Pearson’s chi-square test was used for comparison of
categorical data. The Mann–Whitney U-test was used to
compare two groups, and the Kruskal–Wallis test was used
to compare the acquisition groups by age at infection.
Kaplan–Meier curves were used to display survival data, and
groups were compared by the log-rank test.
The level of signiﬁcance was set at 0.05. For processing
the data, the SPSS 17.0 program package for Windows was
used.
Results
In the study period, 692 individuals had 721 distinct episodes
of SAB. There were 29 re-infections (4.0% of all episodes) in
27 individuals, with a median time to re-infection of 331 days
(range: 50–2632 days). For the whole period, the average
incidence of SAB was 24.5/100 000 adults per year. A 27.3%
increase in annual incidence could be seen from 1995 to
2008, from 22.7 to 28.9 per 100 000 (p 0.012, linear trend
over years). The incidence increased with age, being 6.8/
100 000 per year in the age group 18–34 years and 102.1/
100 000 per year in the age group 75 years and older
(p <0.001, trend for age) (Fig. 1). The mean age at diagnosis
was 62.6 years (range: 18–99 years), and the male/female
ratio was 1.44.
There were 17.3% episodes with a single positive blood
culture in 1995–1999 (34/197, information missing for 19),
19.6% (44/225, information missing for 17) in 2000–2004,
and 17.5% (46/263) in 2005–2008. The respective ﬁgures for
polymicrobial episodes (excluding coagulase-negative staphy-
lococci in one set) with S. aureus growing in more than one
blood culture bottle were 5.1% (10/197), 8.0% (18/225) and
5.3% (14/263) in the same periods.
FIG. 1. Mean annual age-speciﬁc incidence of Staphylococcus aureus
bacteraemia in Iceland per 100 000 population (with 95% CIs).
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Of 721 infections, 334 (46.3%) were nosocomial, 105
(14.6%) healthcare-associated, and 282 (39.1%) community-
acquired. Changes in these proportions were seen during
the study period (Table 1). The median age of those with a
nosocomial infection was 69.0 years (interquartile range
(IQR) 55.0–78.0), that of those with healthcare-associated
infections was 62.0 years (IQR 46.5–73.0), and that of those
with community-acquired infections was 66.0 years (IQR
48.0–75.0) (p 0.012). Of those with community-acquired
infections, 2.5% later had a re-infection; the proportions for
healthcare-associated and nosocomial infections were 7.7%
and 8.2%, respectively (p 0.022).
All-cause 30-day mortality was 17.1% (123/720, one case
lost to follow-up) and 365-day mortality was 33.0% (237/719,
two cases lost to follow-up). Among SAB episodes with a
single positive culture, the 30-day mortality was 17.7% (22/
124). Fig. 2 shows changes in mortality during the study per-
iod. One-year survival curves for different time periods are
shown in Fig. 3. The mortality rate was 4.26 deaths/100 000
adult population per year. It decreased by 64.3%, from 6.6 to
2.4 deaths/100 000 population per year, in the periods
1995–1996 and 2007–2008, respectively (p 0.048, linear
trend over years). Increasing age was associated with higher
SAB 30-day and 365-day mortalities. These were 0% (0/62)
and 3.2% (2/62), respectively, among the patients 18–34
years old, and 27.8% (58/209) and 47.8% (100/209), respec-
tively, among those 75 years and older (p <0.001 for both
trends for age). Thirty-day mortality was 15.8% among males
and 18.9% among females (p 0.27). Thirty-day mortality was
23.4% (78/334) for nosocomial SAB, 15.2% (16/105) for
healthcare-associated SAB, and 10.3% (29/281, one lost to
follow-up) for community-acquired SAB (p <0.001). Mortality
at 365 days was 41.1% (137/333, one lost to follow-up),
36.2% (38/105) and 22.1% (62/281, one lost to follow-up) for
TABLE 1. Characteristics of Staphylococcus aureus bactera-
emia during 1995–2008
1995–1999
(n = 216)
2000–2004
(n = 242)
2005–2008
(n = 263) p-Value
Incidence, per 105 per year
Total >18 years 22.4 23.1 28.9 0.012
18–34 years 3.41 6.67 8.49
35–54 years 12.3 13.9 15.4
55–74 years 55.7 43.3 51.1
>75 years 79.8 94.0 122.8
Mean age (years) 63.0 62.3 62.5 NS
Male (%) 59.3 57.4 60.1 NS
Acquisition (%)
Nosocomial 54.6 45.9 38.4 <0.001
Healthcare-associated 9.7 11.2 14.1 NS
Community-acquired 35.6 43.0 47.5 <0.001
30-day mortality (%)
Total >18 years 22.2 18.7 11.4 0.001
18–34 years 0.0 0.0 0.0
35–54 years 18.2 10.9 3.8
55–74 years 19.6 22.8 7.1
>75 years 35.8 25.4 24.7
365-day mortality (%)
Total >18 years 38.9 32.8 28.2 0.061
18–34 years 0.0 4.2 3.8
35–54 years 29.5 25.5 9.4
55–74 years 35.5 43.5 25.3
>75 years 62.3 33.8 50.6
Mortality rate, per
105 per year
5.0 4.3 3.3 0.048
Resistance (%)
Penicillin 84.3 83.0 78.7 NS
Erythromycin 1.9 3.7 6.8 0.032
Clindamycin 0.9 0.0 3.1 0.028
Oxacillin 0.5 0.4 0.8 NS
NS, non-signiﬁcant.
Mortality rate per 100 000 was calculated by using 30-day case mortality.
p-Values were derived from Kendall’s correlation for trends in data over years,
and by linear trend test (for incidence and mortality rate).
FIG. 2. Mortality from Staphylococcus aureus bacteraemia in Iceland
during 1995–2008. Decreasing 30-day and 365-day mortalities are
seen (p 0.001 and p 0.061, respectively, by Kendall’s correlation for
trends over years).
FIG. 3.One-year survival curves for cases of Staphylococcus aureus
bacteraemia during three different periods (p 0.031, log-rank test).
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the same groups, respectively (p <0.001). One-year survival
curves for the three groups are shown in Fig. 4.
Four cases of bacteraemia caused by methicillin-resistant
S. aureus (MRSA) were noted (0.6%) during the study period;
all of these patients survived. An 80-year-old male without a
known focus for his SAB was diagnosed in 1996, and a
78-year-old male with infected kidney stones as the focus was
diagnosed in 2000. In neither case was a travel history available
from medical records. Two cases occurred in 2008: a
bacteraemic skin infection in a 43-year-old man with psoriasis
who had immigrated from eastern Europe 6 months earlier,
and an endocarditis in a 47-year-old diabetic sailor who had
recently been in England. Susceptibility to penicillin was seen in
18.2% (130/714, lacking information for seven isolates).
Resistance to erythromycin and clindamycin was seen in 4.3%
(31/721) and 1.4% (10/708, lacking information for 13 isolates),
respectively. Temporal changes in susceptibility rates are
shown in Table 1. No correlation was observed between
antibiotic susceptibility and mortality (data not shown).
Discussion
The average annual incidence of 24.5 SAB cases/100 000
among adults is lower than that reported in a Danish study
(30.5 cases/100 000 per year) [2]. Other studies have
reported incidences of 14–41 cases/100 000 per year
[1,3–12]; most of these studies have included children,
among whom the incidence of SAB is generally low. The
present study showed a signiﬁcant, 27% increase in SAB inci-
dence during the period concerned. A similar trend was seen
in two Scandinavian national studies. In Denmark, the inci-
dence rose by 40% from 1981 to 2000, and in Finland it rose
by 55% from 1995 to 2001 [2,3]. A recent study from Min-
nesota, however, did not report a statistically signiﬁcant
increase in SAB incidence from 1998 to 2005 [11]. The
noted increase in SAB incidence could be attributed to an
increase in predisposing risk factors for S. aureus infections,
resulting in a larger population at risk. The population is
getting older, higher numbers of individuals are being diag-
nosed with malignancy, and more people are living with
chronic diseases such as diabetes and obesity [21,22].
The proportion of nosocomial infections (46%) is some-
what lower than generally observed [2,4,12,15,16], but iden-
tical to that of the study from Finland [3]. Most studies have
not included healthcare-associated infections as a special
entity; however, Laupland et al. [4] reported a ratio of 36%.
Because a limited deﬁnition was used, as a result of complete
clinical information not being collected, it is likely that the
proportion of healthcare-associated infections (15%) is
underestimated in the present study. SAB episodes in
patients receiving ambulatory intravenous treatments or
undergoing haemodialysis were considered to be healthcare-
associated only if those patients were admitted to a hospital
in the 90 days prior to bacteraemia. The reason for the low
and decreasing proportion of nosocomial infections in our
study is not clear. It could, in part, be a consequence of the
population-based nature of the study, whereby a higher num-
ber of cases from smaller hospitals were included. Also,
there is a possibility that improved infection control mea-
sures after the year 2001 could be having an effect on reduc-
ing the risk of transmission of S. aureus. These included the
following: the establishment of a department of infection
control in the university hospital in 2001; an MRSA-targeting
search and destroy policy, focusing on screening and isola-
tion of at-risk patients along with eradication of MRSA in
positive individuals, starting in 2001; and a hand hygiene pro-
motional campaign starting in 2004, emphasizing the use of
alcohol hand sanitizers at the university hospital.
The all-cause 30-day mortality of 17.1% for the whole per-
iod is low in comparison with other studies, and our 8.1%
mortality rate for 2007–2008 is among the lowest reported.
To the knowledge of the authors, the lowest mortality rates
are those noted by Melzer et al. [23] of 5.1% and 11.8%
for nosocomial bacteraemia caused by methicillin-sensitive
S. aureus (MSSA) and MRSA, respectively, in two hospitals in
London (including all cases with a positive blood culture for
FIG. 4.One-year survival curves for cases of Staphylococcus aureus
bacteraemia with different modes of acquisition (p <0.001, log-rank
test).
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S. aureus, as was done here). With regard to other national
studies, SAB mortality was 22% in Denmark from 1996 to
2000 and 17% in Finland from 1995 to 2001 (both studies
included all positive cultures) [2,3].
The 1-year all-cause mortalities of 27.9% in 2007–2008
and 33.0% for the whole study period are lower than the
56% in 1988–1992 reported in a study from Israel (excluding
probable contaminations), the 37.6% in 1997–2000 in
Germany reported by Fa¨tkenheuer et al. (including all posi-
tive cultures), and the 46.2% in a recent study on MRSA
bacteraemia [16,19,20]. In the German cohort, there was an
unusually high proportion of nosocomial infections (77%),
which could have contributed to a higher mortality rate
[16]. With regard to those who died within 1 year, it is
interesting that 52% (123/237) of the patients died in the
ﬁrst 30 days and 48% (114/237) in the next 11 months;
these proportions are almost identical to those reported by
Fa¨tkenheuer et al. [16]. All-cause 1-year mortality may
reﬂect both deaths from serious underlying comorbid condi-
tions and long-term sequelae of SAB. This indicates that it
may be important to look not only at the short-term mor-
tality of patients with SAB, and calls for further studies to
assess long-term outcome.
The 68% decrease in 30-day mortality (p 0.001) and the
25% decrease in 365-day mortality (p 0.06) are of special
interest. In-hospital mortality was reported to have
decreased by 37% in Denmark from 1981 to 2000, and by
14% in a Swiss study from 1980 to 2002 [2,14], whereas
other studies have not shown a change in outcome over
time [3,4]. The reasons for the low and decreasing mortality
in Iceland are not clear. A decreasing mortality rate for
bloodstream infections in general has, however, also been
observed, and has in part been thought to reﬂect improve-
ments in supportive treatment [24]. Additionally, the low
mortality rate could be inﬂuenced by the relatively low rates
of antibiotic resistance, including the low rates of MRSA bac-
teraemia usually associated with poor outcome as compared
with MSSA bacteraemia [4,25].
The rate of MRSA bacteraemia (0.6%) reported here is
much lower than those in most previous studies but similar
to that in the national Finnish and Danish studies [2,3,26].
Nosocomial SAB is often seen being caused by MRSA, but
this study demonstrates that MSSA is a signiﬁcant cause of
nosocomial SAB. The reasons for the low level of MRSA
could be the geographical location of Iceland and the search
and destroy policy against MRSA implemented in hospitals in
Iceland as well as in the other Nordic countries and The
Netherlands [27]. The rate of penicillin susceptibility (18%) in
this study is higher than is generally observed among S. aureus
isolates [28,29], possibly making broader sets of treatment
effective. It is nevertheless close to the penicillin susceptibility
of MSSA isolates reported elsewhere [12,30]. Although
increasing levels of resistance against clindamycin and eryth-
romycin were observed, they were considerably lower than
generally observed [12,28,29].
The study has several limitations. All-cause 30-day mortal-
ity is probably an overestimate of mortality resulting from
SAB. Because S. aureus was never considered to be a con-
taminant of blood cultures, possible contaminations have
probably been missed, leading to an underestimation of the
association between true SAB and mortality. As previously
mentioned, another limitation is the limited deﬁnition of
healthcare-associated infections used. Strengths of the study
are that it is based on a whole nation rather than on a lim-
ited population or institution, and that there was long-term
follow-up of the patients in this setting.
In conclusion, this population-based study demonstrates a
signiﬁcant increase in the incidence of SAB during 1995–2008
in Iceland. Concomitantly, it reveals a signiﬁcant decrease in
mortality, towards one of the lowest reported. Further stud-
ies are needed to aid in our understanding of the basis of
these changes, in order to further reduce the incidence and
to improve the outcomes of SAB.
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